Literature DB >> 12912873

NSAIDs: the emperor's new dogma?

I Bjarnason1, K Takeuchi, R Simpson.   

Abstract

The spectacular marketing success of the selective cyclooxygenase 2 (COX-2) inhibitors is largely based on efficacy comparable with conventional non-steroidal anti-inflammatory drugs (NSAIDs) with vastly improved gastrointestinal safety. The additional key to the marketing success is the purity and simplicity of the message-that is, COX-1 inhibition causes the gastrointestinal side effects of NSAIDs (COX-1 dogma) while COX-2 blocking confers the therapeutic benefits (COX-2 dogma). Adherence to the COX dogmas with development of COX-2 selective agents has undoubtedly benefited many patients, but ironically their scientific basis is now seriously challenged by experimentation.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12912873      PMCID： PMC1773807          DOI： 10.1136/gut.52.9.1376

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  31 in total

Review 1.  Cyclooxygenase-2--10 years later.

Authors:  Burkhard Hinz; Kay Brune
Journal:  J Pharmacol Exp Ther       Date:  2002-02       Impact factor: 4.030

Review 2.  Inflammatory bowel disease and spondylarthropathy.

Authors:  S Smale; R S Natt; T R Orchard; A S Russell; I Bjarnason
Journal:  Arthritis Rheum       Date:  2001-12

3.  COX-2 inhibitors.

Authors:  C J Hawkey
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321

4.  Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.

Authors:  L S Simon; A L Weaver; D Y Graham; A J Kivitz; P E Lipsky; R C Hubbard; P C Isakson; K M Verburg; S S Yu; W W Zhao; G S Geis
Journal:  JAMA       Date:  1999-11-24       Impact factor: 56.272

5.  Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat.

Authors:  S Somasundaram; G Sigthorsson; R J Simpson; J Watts; M Jacob; I A Tavares; S Rafi; A Roseth; R Foster; A B Price; J M Wrigglesworth; I Bjarnason
Journal:  Aliment Pharmacol Ther       Date:  2000-05       Impact factor: 8.171

6.  Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge.

Authors:  B Gretzer; N Maricic; M Respondek; R Schuligoi; B M Peskar
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

7.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

8.  COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin.

Authors:  G Sigthorsson; R Crane; T Simon; M Hoover; H Quan; J Bolognese; I Bjarnason
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

9.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

10.  Differential effect of FR122047, a selective cyclo-oxygenase-1 inhibitor, in rat chronic models of arthritis.

Authors:  Takehiro Ochi; Toshio Goto
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739
View more
  8 in total

1.  New dogmas or old?

Authors:  B J R Whittle
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

2.  [NSAID-colonopathy].

Authors:  M Vieth
Journal:  Pathologe       Date:  2006-02       Impact factor: 1.011

3.  Latest concepts on the association between nonsteroidal anti-inflammatory drug-induced small intestinal injury and intestinal bacterial flora.

Authors:  Shunji Fujimori; Choitsu Sakamoto
Journal:  Clin J Gastroenterol       Date:  2013-09-20

Review 4.  Gastroprotective action of glucocorticoid hormones during NSAID treatment.

Authors:  L P Filaretova; T T Podvigina; T R Bagaeva; A Tanaka; K Takeuchi
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

5.  Strictures, diaphragms, erosions or ulcerations of ischemic type in the colon should always prompt consideration of nonsteroidal anti-inflammatory drug-induced lesions.

Authors:  Manfred Stolte; Diana Karimi; Michael Vieth; Hildegard Volkholz; Klaus Dirschmid; Sigrid Rappel; Birgit Bethke
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

Review 6.  Is no NSAID a good NSAID? Approaches to NSAID-associated upper gastrointestinal disease.

Authors:  Stephen Y Chang; Colin W Howden
Journal:  Curr Gastroenterol Rep       Date:  2004-12

Review 7.  The impact of non-steroidal anti-inflammatory drugs on the small intestinal epithelium.

Authors:  Osamu Handa; Yuji Naito; Akifumi Fukui; Tatsushi Omatsu; Toshikazu Yoshikawa
Journal:  J Clin Biochem Nutr       Date:  2013-12-18       Impact factor: 3.114

Review 8.  A Review of Anti-Inflammatory Drug-Induced Gastrointestinal Injury: Focus on Prevention of Small Intestinal Injury.

Authors:  Shunji Fujimori; Katya Gudis; Choitsu Sakamoto
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.